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How should we employ multidimensional indices of COPD?
Ideally, they should serve to work towards 'optimal COPD care',
based on the concept that here-and-now goals should be
integrated with goals to improve long-term outcomes and reduce
future risk.1 However, this integration has (until recently) been
overlooked, largely because multidimensional indices have
usually been developed in selected patient groups and thus lack
external validity in the community.           
In this issue of the PCRJ, Josefin Sundh and colleagues present a
large study assessing the merits of the DOSE (dyspnea, obstruction,
smoking, exacerbations) index in predicting mortality in both primary
and secondary care patients.2 This is an important paper, since it adds
knowledge to the existing applicability of DOSE which previously has
been shown to predict hospitalisation, respiratory failure and
exacerbation risk.3 The authors investigated 1,111 COPD patients
aged 34-75 years, randomly selected from 70 Swedish primary and
secondary care centres. 562 patients had complete data on all DOSE
index components, i.e. MRC dyspnoea scale, forced expiratory volume
in 1 second (FEV1) expressed as percent predicted (FEV1 %pred),
smoking status, and exacerbation rate. Over the course of five years,
116 patients (20.6%) died. Mortality was higher in patients with a
DOSE index score >4 (42.4%) than for lower scores (11.0%)
(p<0.0001). Compared with a DOSE index score of 0–3, the hazard
ratio for mortality was 3.48 (95% CI 2.32 to 5.22) for a score of 4–5,
and 8.00 (95% CI 4.67 to 13.7) for a score of 6–8. Thus, the DOSE
index has now been shown to be associated with mortality in COPD
patients in both primary and secondary care, and can be used to
assess prognosis in addition to other clinically relevant issues.
Originally, DOSE was designed as a predictor of health status,
whereas both BODE (BMI, Obstruction, Dyspnoea, Exercise) and ADO
(Age, Dyspnoea, Obstruction) were derived as predictors of mortality.
ADO has the disadvantage that it is affected by age; younger people
with worse COPD based on MRC or FEV1 score better than their older
counterparts. This is counterintuitive, since one would expect younger
people with advanced COPD to have more serious disease than older
people.4 BODE has been studied extensively, yet has the major
practical drawback that it requires a 6-minute walking test. This stems
from its original development in a rehabilitation setting. However, the
majority of COPD patients are managed in primary care where this test
is not usually performed – although it could be, provided trained
personnel and a 30m hallway were available.  
To use any given index in primary care it should be able to identify
individuals with the highest current burden of disease who are at risk
of future morbidity and mortality. General criteria for the use of an
index in routine clinical practice are that it should be:
(i) simple to record and calculate, 
(ii) the component items should be easy to assess and record, 
(iii) the component items should be clinically important in their own
right, 
(iv) it should be a predictor of a major measure of disease severity e.g.
health status or mortality, and 
(v) the index should be predictive of future exacerbations and health
care consumption.
What is new in this current paper by Sundh et al.? Oga et al.
previously reported on 150 patients from secondary care in Japan, and
compared the DOSE, BODE and ADO indices in relation to mortality.5
They found that all three indices were significantly predictive of 5-year
mortality, but that the BODE and ADO indices performed somewhat
better than the DOSE index. This is hardly surprising, since BODE and
ADO were originally developed as indicators of mortality, whereas the
DOSE index was originally designed to predict health status. The Sundh
paper2 extends this observation in a larger cohort of over 500 patients
from both primary and secondary care, providing firm evidence that
the DOSE index is a very good predictor of respiratory disease-specific
mortality. Furthermore, the Chi-square values in the regression model
used by Sundh et al. show that the DOSE index Chi-square value was
146, followed by MRC dyspnoea scale (116), air flow obstruction (91),
exacerbation frequency (75.5), and smoking (54). This order was
similar to that found in the original DOSE paper.3 Thus, when
considering commonly used severity markers against both health
status (as in the original paper) or mortality (as in the Sundh paper), the
DOSE index is a stronger predictor than any of its individual items. In
addition, while smoking is much vaunted as a predictor of mortality,
smoking was not statistically significantly associated with mortality in
the univariate analysis. The vast majority of patients with COPD are
current or former smokers. However, smoking only accounts for 40-
70% of the attributable risk for COPD.6 In the USA, for example, 20%
of COPD patients are non-smokers, and 20% of COPD mortality
occurs in non-smokers.7 It is therefore worth investigating whether or
not DOSE would be less useful in these individuals.
There are different ways to assess the value of indices in predicting
mortality. In the Sundh paper2 the DOSE index score was examined in
categories, whereas in the Oga paper5 the DOSE score was used as a
continuous variable and Cox’s proportional hazards were used. The
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There were three global epidemics of influenza in the last century –
in 1918-19, 1957-58 and 1968-69 – which resulted in considerable
morbidity and mortality; the number of deaths in these pandemics
has been estimated at 20 to 40 million, 1 million and 1 million,
respectively. The lack of herd immunity to the novel influenza viruses
implicated (i.e. H1N1, H2N2 and H3N2) is believed to have been a
key factor contributing to these very high numbers of deaths.1
The World Health Organization (WHO) subsequently declared
the influenza A, subtype H1N1 virus (which emerged in Mexico in
March 2009) a pandemic in June 2009.2 Production of pandemic
H1N1 2009 influenza monovalent vaccines began soon after
confirmation of outbreaks in Europe and the USA, and in the
autumn of 2009 a worldwide vaccination programme began. The
pandemic vaccine was shown to be highly effective.3 However,
significant global numbers of cases occurred prior to the
implementation of the pandemic vaccination programme. Whilst the
illness severity was in the main mild, early estimates of mortality
attributable to the first pandemic wave revealed an estimated
201,200 respiratory deaths, 80% of which occurred in people aged
under 65.4 Such estimates make no allowance for the illness burden
seen from the same pandemic virus as it became part of the
expected seasonal challenge encountered in the 2010/11 flu season
and subsequently. In the UK, the severity of impact in the 2010/11
season was arguably worse, as gauged by the increased number of
intensive care unit cases and deaths attributable to the H1N1 virus.5
These findings support the argument for the offer of routine
influenza vaccination to healthcare workers, largely to reduce the
nosocomial transmission of influenza to colleagues and vulnerable
patients.
Since 1981, recommendations that healthcare workers be
immunised for influenza have been in place in the UK. However,
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data for the Sundh paper were presented as those with a score of
0-3 compared to those with a score >4. Using Cox regression analyses
the predictive value of the DOSE index was compared to other items.
The methodological processes used by both papers were sound.
However, for clinical use, a measure that can be used to assess change
in status over time is likely to be more helpful than a measure that
assesses prognosis only at one particular moment. Stratifying the
DOSE at a single cut point will limit its utility in this regard. The
possibility that DOSE can be used as a continuous variable, however,
is one that needs to be investigated further.
Data recently presented at the 2012 International Primary Care
Respiratory Group (IPCRG) World Conference in Edinburgh showed
that the DOSE index but not the ADO index was a predictor of future
admissions and exacerbations.8 When taking mortality as an outcome,
the DOSE index has been shown to be a useful predictor of mortality
in both primary and secondary care settings, yet not as strongly as the
BODE and ADO indices. On the other hand, the BODE index is
currently not as useful in a primary care setting where the 6-minute
walk test is not routinely available. The ADO index, while simple to
perform, is strongly tied to the factor ‘age’. The conclusion is that the
DOSE index may be the one index to meet all the criteria required of
an index for use in routine primary care clinical practice, one which
would provide healthcare professionals with a measure of current
status and future risk in their COPD patients.  
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